latest update:
[TrialBase DB]

trial summary · NCT07610135

Psilocybin Efficacy With or Without Pimavanserin Pretreatment

PRISMatic: A Phase 1b Randomized, Double-Armed, Parallel-Group, Placebo-Controlled Trial of Psilocybin Efficacy With or Without Pimavanserin Pretreatment

Trial record from the TrialBase DB dataset, status RECRUITING, condition Mood (Psychological Function), sponsored by Johns Hopkins University. Facts below are exported values from the current release, not inferred or edited prose.

registry NCT07610135phase PHASE1/PHASE2enrollment 20start 2026-10-30

Summary

The brief summary is the registry's published description, capped for length. Field definitions, types, and provenance rules are in the data dictionary.

Twenty healthy adults (≥21 years old) will be enrolled to evaluate the efficacy of a single oral dose of psilocybin (25 mg) administered with or without pretreatment using oral pimavanserin (34 mg) or placebo. Outcome assessments will occur at 1 week and 1 month following psilocybin administration. The purpose of this study is to clarify the receptor-level mechanisms underlying psilocybin's effects on mood and well-being, along with the associated neurophysiologic signatures. These mechanisms will be examined using psychometric scales, autonomic and fMRI-based neurophysiologic markers, and integrated pharmacokinetic/pharmacodynamic modeling.

Source record: https://clinicaltrials.gov/study/NCT07610135

Facts

registry idNCT07610135
primary registryclinicaltrials-gov
recruitment statusRECRUITING
phasePHASE1/PHASE2
study typeINTERVENTIONAL
lead conditionMood (Psychological Function)
sponsorJohns Hopkins University
sponsor classOTHER
enrollment20
start date2026-10-30
primary completion2028-06
completion2028-12
results postednot reported

Conditions

  • Mood (Psychological Function)
  • Well Being
  • Mood
  • Healthy

Interventions

  • Psilocybin
  • Pimavanserin
  • Inactive Placebo

Countries

  • United States

Intervention types: DRUG

Work with this record